期刊文献+

非急性期肺血栓栓塞患者血浆ADAMTS-13及炎症因子变化 被引量:3

Variation in ADAMTS-13 and Inflammatory Factor in Non-acute Pulmonary Thromboembolism Patients
下载PDF
导出
摘要 【目的】探讨肺动脉血栓栓塞症(PTE)患者血管性血友病因子裂解酶(ADAMTS-13)水平及其与炎症反应的关系。【方法】采用酶联免疫吸附的方法 (ELISA)测定25例我院呼吸科门诊随访病程超过3个月的PTE患者、15例健康对照者的外周血血管性血友病因子(v WF)、ADAMTS-13、C反应蛋白(CRP)、白介素6(IL-6)。【结果】PTE组及健康组血浆v WF水平分别为136.89(78.90)ng/m L、57.12(25.23)ng/m L,PTE组v WF水平高于健康组(P<0.001)。PTE组及健康组血浆ADAMTS-13水平分别为213.34±52.39 ng/m L、354.71±79.02 ng/m L,PTE组ADAMTS-13水平显著低于健康对照组(P<0.001)。多重线性回归分析显示血浆ADAMTS-13水平与血浆v WF水平呈负相关(r=-0.490,P=0.013)PTE组及健康组血浆IL-6水平分别为2.59(2.34)pg/m L、1.70(0.71)pg/m L,PTE组IL-6水平高于健康组(P<0.05)。【结论】PTE患者在急性发作后相当长的一段时间内仍存在血浆ADAMTS-13水平的下降及非特异性的炎症反应。 【Objective】 To explore the variation of ADAMTS-13 level and its relationship with inflammation in patients with pulmonary thromboembolism(PTE).【Methods】 ELISA was performed to detect plasma v WF,ADAMTS-13,CRP,IL-6 in 25 patients with PTE,who were diagnosed over 3 months,from respiratory outpatient department of our hospital.Negative control group was established by 15 healthy blood donors.【Results】 The levels of v WF in PTE group and healthy group were 136.89(78.90)ng/m L and 57.12(25.23)ng/m L,respectively.VWF levels were higher in PTE group than in healthy group(P0.001).The plasma level of ADAMTS-13 in PTE group was 213.34±52.39 ng/m L,lower than that in healthy group(354.71±79.02 ng/m L,P0.001).Multiple linear regression analysis showed that there was significantly negative correlation between plasma ADAMTS-13 with v WF(r =-0.490,P= 0.013).The plasma levels of interleukin(IL)-6 in PTE group and healthy group were 2.59(2.34) pg/m L,and 1.70(0.71) pg/m L,respectively.IL-6 levels were higher in PTE group than in healthy group(P 0.05).【Conclusions】 It would be a considerable long time that a decline in plasma ADAMTS-13 levels and non-specific inflammatory reaction existed in patients with PTE after the acute episode.
出处 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2015年第1期131-134,共4页 Journal of Sun Yat-Sen University:Medical Sciences
基金 国家"十二五"科技支撑计划(2011BA11B17)
关键词 肺动脉血栓栓塞症 血管性血友病因子裂解酶 炎症反应 pulmonary thromboembolism ADAMTS-13 inflammation
  • 相关文献

参考文献2

二级参考文献45

  • 1荆志成,邓可武.急性肺动脉血栓栓塞症的溶栓治疗[J].中华医学杂志,2004,84(22):1932-1934. 被引量:20
  • 2邹治鹏,何建国,程显声,赵彦芬,陈白屏,高莹,熊长明,倪新海,荆志诚.230例急性肺动脉血栓栓塞症患者对症治疗、抗凝治疗和溶栓治疗的住院转归[J].中国循环杂志,2006,21(3):219-221. 被引量:27
  • 3Yalamanchili K, Fleisher AG, Lehrman SG, et al. Open pulmonary embolectomy for treatnlent of major pulmonary embolism. Ann Thorae Surg, 2004,77:819-823.
  • 4Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. Blood Rev, 2005, 19 : 179-202.
  • 5PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d' Embolie Pulmonaire par Interruption Cave) randomized study. Circulation, 2005,112:416-422.
  • 6Karmy-Jones R, Jurkovich GJ, Velmahos GC, et al. Practice patterns and outcomes of retrievable vena cava filters in trauma patients : an AAST multicenter study. J Trauma, 2007,62 : 17-24.
  • 7Barral FG. Vena cava filters: why, when, what and how? J Cardiovasc Surg (Torino) , 2008,49:35-49.
  • 8Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism : a European nmlticenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol, 1992, 19:239-245.
  • 9Dalla-Volta S, Palla A, Santolicandro A, et al. PALMS 2: aheplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol, 1992, 20:520-526.
  • 10Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest, 1990, 98: 1473-1479.

共引文献401

同被引文献31

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部